Establishment of Reference Intervals of Cytokeratin 19 Fragment Antigen 21-1 in Korean Adults
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) is useful for predicting and monitoring non-small cell lung cancer prognosis. We established reference intervals (RIs) of CYFRA 21-1 in Korean adults, including those older than 60 years. Data of 4,098 apparently healthy subjects (age range, 20–87 years) were analyzed after excluding those with a history of malignancy, high tumor marker concentrations (except CYFRA 21-1), and/or abnormal findings on a chest computed tomography scan through medical chart review. After removing two outliers, RIs of CYFRA 21-1 were determined using data of 4,096 subjects based on the non-parametric method (2.5th and 97.5th percentiles) according to CLSI guidelines EP28-A3c. The subjects were divided into two and four groups according to sex and age (20–40, 41–50, 51–60, and >60 years), respectively, and the median CYFRA 21-1 concentration was compared between the groups. The RI of CYFRA 21-1 was 0.66–3.84 ng/mL, applicable to both men and women. Regardless of sex, the CYFRA 21-1 concentration increased with age, suggesting that age-dependent RIs of CYFRA 21-1 should be applied. Rather than using a single RI provided by the manufacturer, the RI of CYFRA 21-1 should be continually verified and established in each clinical laboratory.
Abstract
Cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) is useful for predicting and monitoring non-small cell lung cancer prognosis. We established reference intervals (RIs) of CYFRA 21-1 in Korean adults, including those older than 60 years. Data of 4,098 apparently healthy subjects (age range, 20–87 years) were analyzed after excluding those with a history of malignancy, high tumor marker concentrations (except CYFRA 21-1), and/or abnormal findings on a chest computed tomography scan through medical chart review. After removing two outliers, RIs of CYFRA 21-1 were determined using data of 4,096 subjects based on the non-parametric method (2.5th and 97.5th percentiles) according to CLSI guidelines EP28-A3c. The subjects were divided into two and four groups according to sex and age (20–40, 41–50, 51–60, and >60 years), respectively, and the median CYFRA 21-1 concentration was compared between the groups. The RI of CYFRA 21-1 was 0.66–3.84 ng/mL, applicable to both men and women. Regardless of sex, the CYFRA 21-1 concentration increased with age, suggesting that age-dependent RIs of CYFRA 21-1 should be applied. Rather than using a single RI provided by the manufacturer, the RI of CYFRA 21-1 should be continually verified and established in each clinical laboratory.
참고문헌 (20)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Clark SB, "StatPearls" (2022), StatPearls Publishing
- "Cancer facts and figures 2022" (2022)[URL]
- Garcia-Valdecasas Gayo S, "CYFRA 21-1 in patients with suspected cancer : evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value", Adv Lab Med, 1, pp.20200005~ (2020)
- Marrakchi R, "Detection of cytokeratin 19 mRNA and CYFRA 21-1(cytokeratin 19 fragments)in blood of Tunisian women with breast cancer", Int J Biol Markers, 23, pp.238~243 (2008)
- Schalhorn A, "Tumor markers in lung cancer", J Lab Med, 25, pp.353~361 (2001)
- Liu L, "The combination of the tumor markers suggests the histological diagnosis of lung cancer", Biomed Res Int, 2017, pp.2013989~ (2017)
- Yoshimura A, "Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer", Transl Lung Cancer Res, 8, pp.227~234 (2019)
- Kagawa Y, "Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients", Respir Investig, 60, pp.393~399 (2022)
- DeAntoni EP, "Age-and race-specific reference ranges for prostate-specific antigen from a large community-based study", Urology, 48, pp.234~239 (1996)
- Lee MK, "Reevaluation of the reference range of prostate-specific antigen in Korean men", J Clin Pathol Qual Control, 23, pp.221~225 (2001)
- 우희연, "한국 성인에서 각종 종양표지자의 참고범위 설정", Annals of Laboratory Medicine, 28(3), pp.179~184 (2008), 대한진단검사의학회
- 권순석, "Updates on cancer epidemiology in Korea, 2018", 전남의대학술지, 54(2), pp.90~100 (2018), 의과학연구소[DOI]
- CLSI, "Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline–third edition. CLSI EP28-A3c", Clinical and Laboratory Standards Institute, ~ (2010)
- Reed AH, "Influence of statistical method used on the resulting estimate of normal range", Clin Chem, 17, pp.275~284 (1971)
- Parrish AR, "The impact of aging on epithelial barriers", Tissue Barriers, 5, pp.e1343172~ (2017)
- Dai Y, "Reference intervals of cytokeratin-19 fragment(CYFRA 21-1)in healthy adults in China", Clin Lab, 64, pp.123~133 (2018)
- Kao CH, "Cytokeratin fragment 19(CYFRA 21-1)in healthy smokers", Anticancer Res, 19, pp.4545~4546 (1999)
- Karnak D, "Evaluation of Cyfra 21-1 : a potential tumor marker for non-small cell lung carcinomas", Lung, 179, pp.57~65 (2001)
- Kim J, "Lack of clinical utility for CYFRA 21-1 in medical screening", Korean J Fam Pract, 8, pp.73~79 (2018)